Advanced in Peripheral T-Cell Lymphoma

Anca A. Prica

Toronto, ON, CA 
Advanced in Peripheral T-Cell Lymphoma
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Anca Prica practices in Toronto, Canada. Prica is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 104 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles and participated in 1 clinical trial in the study of Peripheral T-Cell Lymphoma.

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada
Kingston, ON K7L3N6, Canada
University Health Network and Mount Sinai Hospital
Ottawa, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
Desensitization of Immunomodulating Agent-Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)
Desensitization of Immunomodulating Agent-Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)
Enrollment Status: Completed
Publish Date: July 24, 2023
Intervention Type: Drug
Study Drugs: Lenalidomide, Pomalidomide
Study Phase: Phase 2
View 2 Less Clinical Trials

104 Total Publications

Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.
Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.
Journal: JCO precision oncology
Published: July 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Prica's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile